Concerns & Risks -- 6/10
Nutrien is a mature, asset-heavy commodity producer, so the primary valuation metric is forward
EV/EBITDA, supplemented by forward P/E. China direct-sales exposure is genuinely low (sub-10%, ~3-5%
of revenue) and regulatory risk is moderate-and-mostly-favorable -- both supportive. But the two
pillars that would push toward a high score are absent: forward valuation sits above the peer average
(~7.0x vs ~6.2x EV/EBITDA), and the catalyst slate is seasonal/incremental rather than a discrete
near-term re-rating event, set against a decelerating forward EPS trajectory and a management team
that chose not to raise guidance after a strong quarter.
Weight: 15%
EV/EBITDA (FY27E)
7.0x
vs peer avg ~6.2x
Above peers
Forward EPS
Declining
FY26 $5.61 → FY28 $4.77
Street models peak erosion
China Exposure
~3-5%
Of company sales; sub-10%
Non-issue
Catalysts
Seasonal
Incremental, not re-rating
Q2 conversion key
Primary Valuation -- Forward EV/EBITDA
| Metric | FY+1 (FY2027E) | Multiple | Peer Avg |
|---|---|---|---|
| EV / EBITDA (primary) | EBITDA $6.06B (consensus) | 7.0x | ~6.2x |
| P / EPS (secondary) | EPS $5.20 (consensus) | 11.8x | n/a |
Full-to-slightly-rich on the cycle's primary lens.
On forward EV/EBITDA, NTR at ~7.0x sits modestly above the peer average (~6.2x; Mosaic ~5.4x, CF
~7.0x) -- a justified premium to Mosaic for the integrated Retail moat and potash cost leadership,
roughly in line with CF. Forward P/E of ~11.8x is reasonable in absolute terms but reflects a
declining EPS trajectory (FY26E $5.61 → FY27E $5.20 → FY28E $4.77), so the "low P/E" is partly an
artifact of normalizing fertilizer prices, not a value signal.
Catalysts
| # | Catalyst | Timing | Note |
|---|---|---|---|
| 1 | Q2 2026 Retail season | Near-term | Largest seasonal proof point; converts Q1 fertilizer strength into FY estimates. Q1 Retail EBITDA recovered to $108M. |
| 2 | Portfolio simplification | 2026+ | Phosphate, Trinidad Nitrogen, Brazil/LatAm retail, Profertil reviews "progressing" but unquantified; Sinofert stake already monetized ($223M). |
| 3 | Potash price/volume durability | 2026 | Realized potash price rose to $264/t in Q1'26 vs $219/t a year ago; guide held, so Q2 confirms. |
| 4 | Cost synergies above $200M target | Ongoing | Management "confident to do more"; running ~1yr ahead of plan. |
| 5 | Capital returns | 2026 | Dividend $2.185/sh (8th straight raise); buyback capacity part of capital allocation. |
Regulatory / Political Risk
| # | Risk | Severity | Detail |
|---|---|---|---|
| 1 | US-China crop-protection tariffs | MEDIUM | Raise Retail input costs but management deems passable-through; deemed not material to 2025 earnings. |
| 2 | M&A integration / portfolio spin execution | MEDIUM | Portfolio-review story "in progress" for multiple quarters without quantified outcomes; dis-synergy/stranded-cost risk. |
| 3 | Fertilizer benchmark cyclicality | MEDIUM | Price-taker across all segments; realizations track global benchmarks that can roll over. |
| 4 | Nitrogen import tariffs into NA | FAVORABLE | Net positive for NTR's domestic supply position. |
| 5 | Export controls (Russia/Belarus/China) | FAVORABLE | Food-security politics cut both ways but have generally tightened supply in NTR's favor. |
Bull case
| # | Factor | Detail |
|---|---|---|
| 1 | Cycle inflecting up | Q1'26 sales +19% and adj EBITDA +30% YoY ($1.11B vs $852M). |
| 2 | Integrated low-cost leader | Wide Retail moat and #1 potash position; peer-tightening global supply (Russia/Belarus/China constraints) as structural support. |
| 3 | Conservative reaffirmed guidance | Leaves upside if Potash/Nitrogen pricing holds through Q2. |
| 4 | Self-help FCF levers | Portfolio simplification and synergies above plan add FCF; disciplined capital allocation. |
| 5 | Recovering cycle at reasonable multiple | ~12x earnings on a recovering cycle with a healthy FCF profile. |
Bear case
| # | Factor | Detail |
|---|---|---|
| 1 | Price-taking cyclical at full multiple | Full-to-rich forward EV/EBITDA (~7.0x vs ~6.2x peers) on declining consensus EPS (FY26 $5.61 → FY28 $4.77). |
| 2 | Guidance not raised after a beat | Management beat Q1 but refused to raise guidance -- a tell they see fertilizer prices as cyclical, not durable. |
| 3 | Leverage limits buyback firepower | Net debt/EBITDA at 1.8-2.1x constrains the pace of returns. |
| 4 | Catalysts seasonal, not transformational | No discrete near-term re-rating event; portfolio-review story unquantified for multiple quarters. |
| 5 | Long-dated supply threat | BHP's Jansen mine ($14B, Phase 1 mid-2027) adds ~10% of world demand by 2031, pressuring the potash oligopoly. |
Score rationale
Score of 6/10 maps to the middle of the rubric: low China exposure and mostly-favorable regulatory backdrop are supportive, but full valuation and a seasonal/incremental catalyst slate against a decelerating forward EPS trajectory keep it from a higher score.
Supportive (why not lower): China direct-sales exposure is genuinely low (sub-10%, ~3-5% of company revenue) and partly offset — NTR benefits when China restricts its own phosphate/urea exports, tightening global supply. Regulatory risk is moderate-and-mostly-favorable (nitrogen import tariffs and export controls tend to tighten supply in NTR's favor). Catalysts are real, led by Q2 seasonal conversion and above-plan synergies.
Why not higher: Forward valuation sits above the peer average (~7.0x vs ~6.2x EV/EBITDA), the catalyst slate is seasonal/incremental rather than a discrete near-term re-rating event, forward EPS is decelerating (FY26 $5.61 → FY28 $4.77), and management chose not to raise guidance after a strong quarter. This is a price-taking commodity cyclical at a full-to-rich multiple with real execution/leverage watch items.
Data sourced from Daloopa (company_id 11163) for fundamentals, FMP for quote/consensus (2026-06-29), and public sources for peer multiples and China exposure.